drugset / Trial / NCT03961347
Lactobacillus Johnsonii Supplementation in Adults With T1D
Phase 2
Completed
46 enrolled
University of Florida
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupQuadruple-blindSupportive care
Summary
While genetics demonstrated a major risk factor for the development of type 1 diabetes (T1D), microbiota dysbiosis has been suggested as an elicitor in immunological tolerance and of beta cell autoimmunity. The probiotic Lactobacillus johnsonii N6.2 may prevent or restore the gut flora and show systemic impacts and adaptive immunity in the T1D population thereby preserving beta cell function.
Timeline
- Start
- 2020-02-01
- Primary completion
- 2026-03-18
- Completion
- 2026-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lactobacillus johnsonii N6.2 | Other / unclassified | 1e+09 unknown | — |